This site is intended for UK healthcare professionals only.
If you are not a UK healthcare professional, click here.
Professor Alastair Greystoke discusses a real-world case study involving treatment decisions in ALK+ aNSCLC across lines of therapy.
ALK+, anaplastic lymphoma kinase positive; aNSCLC, advanced non-small cell lung cancer.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
This website is intended for UK healthcare professionals and includes promotional content, medical education and professional support resources about Takeda Oncology products and related therapy areas. This website is developed and funded by Takeda.
©2026 Takeda Pharmaceutical Company Limited. All rights reserved
C-APROM/GB/OG/0141 | May 2026
You will be redirected to an external website that is neither owned or controlled by Takeda Ltd. Takeda does not review, endorse or control the content of any non-Takeda site.
Takeda Ltd is not responsible for the accuracy, content, practices or standards of any non-Takeda resources accessed through a link on this site.
Do you wish to continue?
Do you wish to continue?